Join Us | Contact Us | Sitemap | Korean

      About Us | Report | Custom Research | Support


Login

Category

Telecom/Wireless

Electronic

Digital Devices/Media/Broadcasting

Information Technology

Energy

Life Science

Chemical/Advanced Materials

Automotive

Environment

Consumer Goods

Marketing/Advertising

Finance

Construction

Transportation

Consumer Survey

Defence/Aerospace

Food/Beverage

Heavy Industry

Education

Industrial Machinery

International Trades

Sports/Leisure

Marine/Ship Building

Fashion

Government/Policy

Industrial Arts/Jewellery

Company Profiles

ETC

 
Location : HOME > Report > Life Science > Pharmaceuticals
Global Nanotechnology Drug Delivery Market 2012-2016
Publisher Infiniti Research Limited
Date 2013-03
Quantity 35 pages
Type Report
Price

Print

TechNavio's analysts forecast the Global Nanotechnology Drug Delivery market to grow at a CAGR of 73.97 percent over the period 2012-2016. One of the key factors contributing to this market growth is the low R&D cost. The Global Nanotechnology Drug Delivery market has also been witnessing an increase in customer support services. However, the increasing safety concerns could pose a challenge to the growth of this market.

TechNavio's report, Global Nanotechnology Drug Delivery Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it covers the Global Nanotechnology Drug Delivery market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

The key vendors dominating this space are IOTA NanoSolutions Ltd., Lena Nanoceutics Ltd., GlaxoSmithKline plc, Celgene Corp., and SkyePharma plc.

The other vendors mentioned in the report are Merck & Co. Inc., Pfizer Inc., AlphaRx Inc., Amgen Inc., Angiotech Pharmaceuticals Inc., Biophan Technologies Inc., Calando Pharmaceuticals Inc., Cephalon Inc., Cerulean Pharma Inc., Copernicus Therapeutics Inc., CritiTech Inc., CytImmune Sciences Inc., Elan Corp. plc, Debiotech SA, F. Hoffmann-La Roche Ltd., Nano Interface Technology Inc., Spherics Inc., Spectrum Pharmaceuticals Inc., SoluBest Ltd., Sigma-Tau Pharmaceuticals Inc., PharmaNova Inc., Particle Sciences Inc., Novavax Inc., Nanotherapeutics Inc., NanoSight Ltd., NanoCarrier Co. Ltd., NanoBioMagnetics Inc., Nano Interface Technology Inc., Merck Sharp & Dohme Corp., Kuecept Ltd., and Izon Science Ltd.

Key questions answered in this report:

What will the market size be in 2016 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of each of these key vendors?

You can request one free hour of analyst time when you purchase this report. Details provided within the report.


About Us | Privacy Polocy | Terms & Conditions | Delivery/Payment

Samwon Bldg., 210-1 Nonhyun-dong, Gangnam-gu, 135-996, Seoul, Korea | LNH, Inc.
Tel : 82-2-554-0001 / Fax : 82-2-3444-5501 / E-mail : sales@landh.co.kr
Copyright ¨Ï 2008 LNH, Inc. All rights reserved.